Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of FG-M131 in TRBC1-positive relapsed/refractory peripheral T-cell lymphoma
CTR20262972Phase 2Active
- Sponsor
- Mingji Biopharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FG-M131 in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by Mingji Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
FG-M131
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on CTR20262972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262972.